🔗 Permalink

Inventor profile of:

Moise Azria

City:

Basel

Country:

Switzerland

Published Applications:

Last publication date:

2015-09-10

Top Assignees for applications by Moise Azria

The entities that hold a legal rights for patent applications filed by inventor Azria Moise:

NOVARTIS AG 19 Basel, Switzerland
Emisphere Technologies, Inc. 6 Cedar Knolls, NJ United States
NORDIC BIOSCIENCE A/S 1 Herlev, Denmark
Emisphere Technologies, Inc. 1 Roseland, NJ United States

Recent patent applications by Azria Moise

Moise Azria from Basel, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2015-09-10

US20150250729A1

Human necessities

Pharmaceutical composition

#2 | 2014-09-18

US20140271735A1

Human necessities

USE OF CALCITONIN IN OSTEOARTHRITIS

#3 | 2013-09-05

US20130230593A1

Human necessities

Method for treating bone related diseases and calcium disorders

#4 | 2012-10-18

US20120264834A1

Chemistry; metallurgy

Disodium salts, monohydrates, and ethanol solvates for delivering active agents

#5 | 2012-08-30

US20120219603A1

Human necessities

Use of Calcitonin for the Treatment of RA

#6 | 2012-04-12

US20120088833A1

Human necessities

Modified amino acid for the inhibition of platelet aggregation

#7 | 2012-04-12

US20120088725A1

Human necessities

5-CNAC as oral delivery agent for parathyroid hormone fragments

#8 | 2011-10-13

US20110251125A1

Chemistry; metallurgy

Disodium salts, monohydrates, and ethanol solvates for delivering active agents

#9 | 2011-09-08

US20110218148A1

Human necessities

PHARMACEUTICAL COMPOSITION

#10 | 2011-04-21

US20110092426A1

Human necessities

ORAL CALCITONIN COMPOSITIONS AND APPLICATIONS THEREOF

#11 | 2010-11-04

US20100278881A1

Human necessities

Use of calcitonin in osteoarthritis

#12 | 2010-09-30

US20100247608A1

Human necessities

Pharmaceutical compositions comprising hGH for oral delivery

#13 | 2010-04-22

US20100099621A1

Chemistry; metallurgy

Disodium salts, monohydrates, and ethanol solvates for delivering active agents

#14 | 2009-10-22

US20090264367A1

Human necessities

5-CNAC AS ORAL DELIVERY AGENT FOR PARATHYROID HORMONE FRAGMENTS

#15 | 2009-02-19

US20090048157A1

Human necessities

USE OF ORGANIC COMPOUNDS

#16 | 2008-11-13

US20080280817A1

Human necessities

MODIFIED AMINO ACID FOR THE INHIBITION OF PLATELET AGGREGATION

#17 | 2008-10-30

US20080269134A1

Chemistry; metallurgy

Disodium salts, monohydrates, and ethanol solvates for delivering active agents

#18 | 2008-10-16

US20080255048A1

Human necessities

Pharmaceutical Composition

#19 | 2008-09-25

US20080234179A1

Human necessities

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

#20 | 2008-09-18

US20080226737A1

Human necessities

Use of calcitonin for the treatment of RA

#21 | 2008-05-22

US20080119411A1

Human necessities

Orally administering parathyroid hormone and calcitonin

#22 | 2007-10-04

US20070232524A1

Human necessities

Oral administration of calcitonin

#23 | 2007-03-22

US20070065505A1

Human necessities

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

#24 | 2006-09-28

US20060217313A1

Human necessities

5-CNAC as oral delivery agent for parathyroid hormone fragments

#25 | 2006-08-31

US20060194722A1

Human necessities

Use of calcitonin in osteoarthritis

#26 | 2006-06-22

US20060135402A1

Human necessities

Oral administration of calcitonin

#27 | 2006-05-23

US10006311

Pharmaceutical compositions for the oral delivery of pharmacologically active agents

#28 | 2006-05-18

US20060106110A1

Human necessities

Modified amino acid for the inhibition of platelet aggregation

InventorID:

424270 ⎘